Biological therapies in psoriasis - revisited

Maria-Isabela Sârbu; Simona-Roxana Georgescu; Mircea Tampa; Alexandra-Elena Sârbu; Olga Simionescu

doi:10.1515/rjim-2017-0045

.blurhash-client-img { display: none !important; }

Biological therapies in psoriasis - revisited

Romanian Journal of Internal Medicine

Volume 56 (2018): Issue 2 (June 2018)

By: Maria-Isabela Sârbu, Simona-Roxana Georgescu, Mircea Tampa, Alexandra-Elena Sârbu and Olga Simionescu

Open Access

|May 2018

Abstract

Psoriasis is a chronic, immune mediated disorder affecting approximately 2% of the population. Even in our days, patients with psoriasis are confronted with stigmatization and social rejection. As a result, their quality of life is significantly impaired. Biological therapies have revolutionized the treatment of moderate to severe psoriasis. The aim of this paper is to look over the most important biological therapies available for the management of plaque-type psoriasis.

References

1. LOWELL A. GOLDSMITH, STEPHEN I. KATZ, BARBARA A. GILCHREST, et al. Fitzpatrick’s Dermatology in General Medicine, 8^th Ed., McGrawHill, 2012.
Search in Google Scholar Back to article
2. BOLOGNIA JEAN L, JOSEPH L. JORIZZO, SCHAFFER JULIE V. Dermatology. Elsevier, 3 Ed, 2012.
Search in Google Scholar Back to article
3. BRAUN-FALCO O., PLEWIG G, WOLFF HH, M. LANDTHALER. Braun-Falco's Dermatology. Third edition. Springer. 2009.
Search in Google Scholar Back to article
4. MAHIL SK, CAPON F, BARKER JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. In: Seminars in immunopathology (Vol. 38, No. 1, pp. 11-27). Springer, Berlin, Heidelberg, 2016.10.1007/s00281-015-0539-8470657926573299
Search in Google Scholar Back to article
5. TAMPA M, NICOLAE IL, ENE CD, et al. Vitamin C and Thiobarbituric Acid Reactive Substances (TBARS) in Psoriasis Vulgaris Related to Psoriasis Area Severity Index (PASI). REVISTA DE CHIMIE. 2017; 68(1):43-7.10.37358/RC.17.1.5385
Search in Google Scholar Back to article
6. ŁAKUTA P, MARCINKIEWICZ K, BERGLER-CZOP B, et al. How does stigma affect people with psoriasis? Advances in Dermatology and Allergology/Postẹpy Dermatologii i Alergologii. 2017; 34(1):36.10.5114/pdia.2016.62286532910128261029
Search in Google Scholar Back to article
7. OWCZAREK K, JAWORSKI M. Quality of life and severity of skin changes in the dynamics of psoriasis. Advances in Dermatology and Allergology/Postẹpy Dermatologii i Alergologii. 2016; 33(2):102.10.5114/pdia.2015.54873488477327279818
Search in Google Scholar Back to article
8. MANTOVANI L, MEDAGLIA M, PIACENTINI P, et al. Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatology and therapy. 2016; 6(2):151-67.10.1007/s13555-016-0114-9490610827083437
Search in Google Scholar Back to article
9. GHORBANIBIRGANI A, FALLAHI-KHOSHKNAB M, ZAREA K, et al. The Lived Experience of Psoriasis Patients from Social Stigma and Rejection: A Qualitative Study. Iranian Red Crescent Medical Journal. 2016; 18(7).10.5812/ircmj.27893502676627656290
Open DOI Search in Google Scholar Back to article
10. BAKER BS. From arsenic to biologicals: a 200 year history of psoriasis. Garner Press; 2008.
Search in Google Scholar Back to article
11. PATHIRANA D, ORMEROD AD, SAIAG P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology. 2009; 23(s2):1-70.
Search in Google Scholar Back to article
12. TONY BURNS, STEPHEN BREATHNACH, NEIL COX, et al. Rook's textbook of dermatology. Eighth Edition, Wiley Blackwell, 2010.10.1002/9781444317633
Search in Google Scholar Back to article
13. ZAIDI A, MENG Q, POPKIN D. Can we repurpose FDA-approved alefacept to diminish the HIV reservoir? Immunotherapy (Los Angeles, Calif.). 2015; 1(1).10.4172/2471-9552.1000104
Search in Google Scholar Back to article
14. DUNN LK, FELDMAN SR. Alefacept treatment for chronic plaque psoriasis. Skin Therapy Lett. 2010; 15(4):1-3.
Search in Google Scholar Back to article
15. KAFFENBERGER BH, KAFFENBERGER TM, WONG HK. Immunotargeting in the management of psoriasis. Immuno Targets and Therapy. 2013; 2:51.10.2147/ITT.S32038492835827471688
Search in Google Scholar Back to article
16. ELLIS CN, KRUEGER GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New England Journal of Medicine. 2001; 345(4):248-55.10.1056/NEJM20010726345040311474662
Search in Google Scholar Back to article
17. SIVAMANI RK, CORREA G, ONO Y, et al. Biological therapy of psoriasis. Indian journal of dermatology. 2010; 55(2):161.10.4103/0019-5154.62754288752220606887
Search in Google Scholar Back to article
18. LEBWOHL M, CHRISTOPHERS E, LANGLEY R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Archives of dermatology. 2003; 139(6):719-27.10.1001/archderm.139.6.71912810502
Search in Google Scholar Back to article
19. WCISŁO-DZIADECKA D, ZBICIAK M, BRZEZIŃSKA-WCISŁO L, et al. Anti-cytokine therapy for psoriasis-not only TNF-α blockers. Overview of reports on the effectiveness of therapy with IL-12/IL-23 and T and B lymphocyte inhibitors. Advances in Hygiene & Experimental Medicine/Postepy Higieny i Medycyny Doswiadczalnej. 2016; 70.
Search in Google Scholar Back to article
20. GORDON KB, PAPP KA, HAMILTON TK, et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama. 2003; 290(23):3073-80.10.1001/jama.290.23.307314679270
Search in Google Scholar Back to article
21. WHARTON JR KA, QUIGLEY C, THEMELES M, et al. JC polyomavirus abundance and distribution in progressive multifocal leukoencephalopathy (PML) brain tissue implicates myelin sheath in intracerebral dissemination of infection. PloS one. 2016; 11(5):e0155897.10.1371/journal.pone.0155897487143727191595
Search in Google Scholar Back to article
22. SCHWAB N, ULZHEIMER JC, FOX RJ, et al. Fatal PML associated with efalizumab therapy. Insights into integrin αLβ2 in JC virus control. Neurology. 2012; 78(7):458-67.10.1212/WNL.0b013e3182478d4b328005222302546
Open DOI Search in Google Scholar Back to article
23. TAVAZZI E, FERRANTE P, KHALILI K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clinical Microbiology and Infection. 2011; 17(12):1776-80.10.1111/j.1469-0691.2011.03653.x465950322082208
Search in Google Scholar Back to article
24. TAN JK, APHALE A, MALAVIYA R, et al. Mechanisms of action of etanercept in psoriasis. In: Journal of Investigative Dermatology Symposium Proceedings 2007 (Vol. 12, No. 1, pp. 38-45). Elsevier.10.1038/sj.jidsymp.565003717502868
Search in Google Scholar Back to article
25. LEONARDI CL, POWERS JL, MATHESON RT, et al. Etanercept as monotherapy in patients with psoriasis. New England Journal of Medicine. 2003; 349(21):2014-22.10.1056/NEJMoa03040914627786
Search in Google Scholar Back to article
26. FERNÁNDEZ-TORRES RM, PARADELA S, FONSECA E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. Journal of Dermatological Treatment. 2014; 25(1):54-6.10.3109/09546634.2012.75525423210771
Search in Google Scholar Back to article
27. Summary of product characteristics Enbrel. [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf
Search in Google Scholar Back to article
28. PALLER AS, SIEGFRIED EC, LANGLEY RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. New England Journal of Medicine. 2008; 358(3):241-51.10.1056/NEJMoa06688618199863
Search in Google Scholar Back to article
29. CARAZO JL, SANTOS LM, MARTINEZ VO. Safety of Etanercept in Psoriasis. Drug safety. 2006; 29(8):675-85.10.2165/00002018-200629080-00004
Search in Google Scholar Back to article
30. GORDON KB, LANGLEY RG, LEONARDI C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. Journal of the American Academy of Dermatology. 2006; 55(4):598-606.10.1016/j.jaad.2006.05.027
Open DOI Search in Google Scholar Back to article
31. MENTER A, TYRING SK, GORDON K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. Journal of the American Academy of Dermatology. 2008; 58(1):106-15.10.1016/j.jaad.2007.09.010
Search in Google Scholar Back to article
32. SAURAT JH, STINGL G, DUBERTRET L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). British Journal of Dermatology. 2008; 158(3):558-66.10.1111/j.1365-2133.2007.08315.x
Search in Google Scholar Back to article
33. PAPP K, THAÇI D, MARCOUX D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. The Lancet. 2017.10.1016/S0140-6736(17)31189-3
Open DOI Search in Google Scholar Back to article
34. CARRASCOSA CARRILLLO JM, TORO MONTECINOS M, BALLESCÁ LÓPEZ F, et al. Correlation between trough serum levels of Adalimumab and absolute PASI score in a series of patients with psoriasis. Journal of Dermatological Treatment. 2017 Jun 12(just-accepted):1-20.
Search in Google Scholar Back to article
35. TRACZEWSKI P, RUDNICKA L. Adalimumab in dermatology. British journal of clinical pharmacology. 2008; 66(5):618-25.10.1111/j.1365-2125.2008.03263.x
Search in Google Scholar Back to article
36. GALL JS, KALB RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008; 2(1):115-24.
Search in Google Scholar Back to article
37. REICH K, NESTLE FO, PAPP K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. The Lancet. 2005; 366(9494):1367-74.10.1016/S0140-6736(05)67566-6
Search in Google Scholar Back to article
38. MENTER A, FELDMAN SR, WEINSTEIN GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 2007; 56(1):31-e1.10.1016/j.jaad.2006.07.01717097378
Search in Google Scholar Back to article
39. FELDMAN SR, GORDON KB, BALA M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. British Journal of Dermatology. 2005; 152(5):954-60.10.1111/j.1365-2133.2005.06510.x15888152
Search in Google Scholar Back to article
40. TAKAHASHI H, TSUJI H, ISHIDA-YAMAMOTO A, et al. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. The Journal of dermatology. 2013; 40(1):39-42.10.1111/j.1346-8138.2012.01679.x23039179
Search in Google Scholar Back to article
41. LEONARDI CL, KIMBALL AB, PAPP KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-74.10.1016/S0140-6736(08)60725-4
Search in Google Scholar Back to article
42. PAPP KA, LANGLEY RG, LEBWOHL M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84.10.1016/S0140-6736(08)60726-6
Search in Google Scholar Back to article
43. PAPP KA, GRIFFITHS CE, GORDON K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. British Journal of Dermatology. 2013; 168(4):844-54.10.1111/bjd.1221423301632
Search in Google Scholar Back to article
44. LANGLEY RG, LEBWOHL M, KRUEGER GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. British Journal of Dermatology. 2015; 172(5):1371-83.10.1111/bjd.1346925307931
Search in Google Scholar Back to article
45. GRIFFITHS CE, STROBER BE, VAN DE KERKHOF P, et al. Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis. New England Journal of Medicine. 2010; 362(2):118-28.10.1056/NEJMoa081065220071701
Search in Google Scholar Back to article
46. Summary of product characteristics Stelara [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf
Search in Google Scholar Back to article
47. KOFOED K, SKOV L, ZACHARIAE C. New drugs and treatment targets in psoriasis. Acta dermato-venereologica. 2015; 95(2):133-9.10.2340/00015555-193125111317
Search in Google Scholar Back to article
48. GODSE K. Secukinumab-First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis. Indian journal of dermatology. 2017; 62(2):195.10.4103/ijd.IJD_233_16536314528400641
Search in Google Scholar Back to article
49. Prescribing information Cosentyx [Accessed 22.06.2017]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf
Search in Google Scholar Back to article
50. PAPP KA, LANGLEY RG, SIGURGEIRSSON B, et al. Efficacy and safety of secukinumab in the treatment of moderate-tosevere plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. British Journal of Dermatology. 2013; 168(2):412-21.10.1111/bjd.1211023106107
Search in Google Scholar Back to article
51. LANGLEY RG, ELEWSKI BE, LEBWOHL M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. New England Journal of Medicine. 2014; 371(4):326-38.10.1056/NEJMoa131425825007392
Search in Google Scholar Back to article
52. FALA L. Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis. American Health & Drug Benefits. 2016; 9(Spec Feature):60.
Search in Google Scholar Back to article
53. Summary of product characteristics Talz. [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf
Search in Google Scholar Back to article
54. GORDON KB, BLAUVELT A, PAPP KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New England Journal of Medicine. 2016; 375(4):345-56.10.1056/NEJMoa151271127299809
Search in Google Scholar Back to article
55. GRIFFITHS CE, REICH K, LEBWOHL M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015; 386(9993):541-51.10.1016/S0140-6736(15)60125-8
Search in Google Scholar Back to article
56. HANLEY TL, YIU ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Therapeutics and clinical risk management. 2017; 13:315.10.2147/TCRM.S111107
Search in Google Scholar Back to article
57. GOTTLIEB AB, LACOUR JP, KORMAN N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. Journal of the European Academy of Dermatology and Venereology. 2017; 31(4):679-85.10.1111/jdv.13990
Open DOI Search in Google Scholar Back to article
58. GUDJONSSON JE, JOHNSTON A, ELLIS CN. Novel systemic drugs under investigation for the treatment of psoriasis. Journal of the American Academy of Dermatology. 2012; 67(1):139-47.10.1016/j.jaad.2011.06.037
Search in Google Scholar Back to article
59. DAMSKY W, KING BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology. 2017.10.1016/j.jaad.2016.12.005
Search in Google Scholar Back to article
60. SHREBERK-HASSIDIM R, RAMOT Y, ZLOTOGORSKI A. Janus kinase inhibitors in dermatology: A systematic review. Journal of the American Academy of Dermatology. 2017.10.1016/j.jaad.2016.12.004
Open DOI Search in Google Scholar Back to article
61. PAPP KA, MENTER MA, ABE M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology. 2015; 173(4):949-61.10.1111/bjd.14018
Search in Google Scholar Back to article
62. BACHELEZ H, VAN DE KERKHOF PC, STROHAL R, KUBANOV A, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. The Lancet. 2015; 386(9993):552-61.10.1016/S0140-6736(14)62113-9
Search in Google Scholar Back to article
63. PORTS WC, KHAN S, LAN S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. British Journal of Dermatology. 2013; 169(1):137-45.10.1111/bjd.12266376119023387374
Search in Google Scholar Back to article
64. Summary of product characteristics Otezla [Accessed 22.06.2017]. Available at: https://ec.europa.eu/health/documents/community-register/2015/20150115130395/anx_130395_en.pdf
Search in Google Scholar Back to article
65. PAPP K, REICH K, LEONARDI CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Journal of the American Academy of Dermatology. 2015; 73(1):37-49.10.1016/j.jaad.2015.03.04926089047
Search in Google Scholar Back to article
66. MUGHAL F, BARKER J, CAWSTON H, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the Uk. Journal of the American Academy of Dermatology. 2016; 74(5):AB243.10.1016/j.jaad.2016.02.950
Search in Google Scholar Back to article
67. European Agency of Medicines: Biosimilars. [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp&mid=WC0b01ac0580bb8fda
Search in Google Scholar Back to article
68. MAZUR M, OLEK-HRAB K, KARCZEWSKI J, et al. Biosimilars in dermatology. Advances in Dermatology and Allergology/Postẹpy Dermatologii i Alergologii. 2015; 32(5):384.10.5114/pdia.2014.44026469281326759547
Search in Google Scholar Back to article
69. RADTKE MA, AUGUSTIN M. Biosimilars in psoriasis: what can we expect? JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2014; 12(4):306-12.10.1111/ddg.1229424698590
Open DOI Search in Google Scholar Back to article
70. NAST A, ROSUMECK S, SEIDENSCHNUR K. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2015; 13(4):294-300.10.1111/ddg.1262125819235
Search in Google Scholar Back to article
71. PUIG L. Biosimilars in psoriasis 2015: what is next? Journal of the European Academy of Dermatology and Venereology. 2016; 30(3):467-9.10.1111/jdv.1284325389042
Search in Google Scholar Back to article
72. GRIFFITHS CE, THAÇI D, GERDES S, et al. The EGALITY study: A confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. British Journal of Dermatology. 2016.10.1111/bjd.1515227787890
Search in Google Scholar Back to article
73. DAPAVO P, VUJIC I, FIERRO MT, et al. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 2016; 75(4):736-9.10.1016/j.jaad.2016.04.06827473452
Search in Google Scholar Back to article
74. TICHY M, KOPOVA R, STERNBERSKY J. First experience with therapy of severe forms of psoriasis with biosimilar infliximab. Journal of the European Academy of Dermatology and Venereology. 2016; 30(3):491-3. Received November 9^th, 201710.1111/jdv.1287625418715
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.1515/rjim-2017-0045 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749

Journal RSS Feed

Language: English

Page range: 75 - 84

Submitted on: Nov 9, 2017

Published on: May 17, 2018

Published by: N.G. Lupu Internal Medicine Foundation

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

psoriasis,

biological therapies,

TNF-α,

IL-17,

Related subjects:

Internal medicine, other,

Cardiology,

Gastroenterology,

Rheumatology

© 2018 Maria-Isabela Sârbu, Simona-Roxana Georgescu, Mircea Tampa, Alexandra-Elena Sârbu, Olga Simionescu, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 56 (2018): Issue 2 (June 2018)